文献速递中医内科中药与中成药合理使用

散寒化湿颗粒治疗新型冠状病毒肺炎有效性与安全性的随机对照试验研究方案与统计分析计划

Effectiveness and safety analysis of SanHanHuaShi granules for the treatment of coronavirus disease 2019: Study protocol and statistical analysis plan for a randomized, parallel-controlled, open-label clinical trial.
PubMed 文献 · Front Pharmacol · 2022-08-16

本文为一项7天、随机、平行对照、开放标签、阳性药非劣效临床试验的研究方案与统计分析计划,拟纳入240例轻型和普通型COVID-19患者,按1:1随机接受散寒化湿颗粒或连花清瘟颗粒治疗,主要结局为临床症状恢复率,旨在确证散寒化湿颗粒的有效性与安全性。

要点

  • 散寒化湿颗粒已纳入国家卫健委第六至九版COVID-19诊疗方案。
  • 研究采用阳性药对照非劣效设计,对照药为连花清瘟颗粒。
  • 主要结局为临床症状恢复率,次要结局包括核酸转阴时间与住院时间。

核心结论

  • 本研究方案旨在通过随机对照试验确证散寒化湿颗粒治疗COVID-19的有效性与安全性。

研究设计与样本

  • 研究为7天、随机、平行对照、开放标签、阳性药非劣效临床试验。
  • 计划纳入240例轻型与普通型COVID-19患者,按1:1随机分为散寒化湿颗粒组与连花清瘟颗粒组。

主要发现

  • 既往回顾性队列研究显示散寒化湿颗粒可显著降低轻型和普通型COVID-19的严重程度。
  • 目前缺乏高质量随机对照临床研究证实散寒化湿颗粒的临床有效性。

关键数值与推荐

  • 主要结局为临床症状恢复率。
  • 次要结局包括临床症状恢复时间、SARS-CoV-2核酸转阴时间、核酸转阴率、住院时间、退热时间、转重症率及单一症状恢复时间与恢复率。

临床怎么用

  • 研究结果将为散寒化湿颗粒治疗COVID-19的有效性与安全性提供证据。
  • 研究方案与统计分析计划旨在提高临床研究过程的完整性与数据透明度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Coronavirus disease 2019 (COVID-19) was declared a global pandemic in March 2020 by the World Health Organization (WHO). As of July 2, 2022, COVID-19 has caused more than 545 million infections and 6.3 million deaths worldwide, posing a significant threat to human health. Currently, there is still a lack of effective prevention and control strategies for the variation and transmission of SARS-CoV-2. Traditional Chinese medicine (TCM), which has a unique theoretical system, has treated various conditions for thousands of years. Importantly, recent studies have revealed that TCM contributed significantly to COVID-19. SanHanHuaShi (SHHS) granules, a Chinese herbal medicine, which has been included in Protocol for the Diagnosis and Treatment of Novel Coronavirus Disease 2019 (6th to 9th editions) issued by the National Health Commission of China and used to prevent and treat COVID-19 disease. A previous retrospective cohort study showed that SHHS could significantly reduce the severity of mild and moderate COVID-19. However, there is an absence of high-quality randomized controlled clinical studies to confirm the clinical effectiveness of SHHS. Therefore, a clinical study protocol and a statistical analysis plan were designed to investigate the efficacy and safety of SHHS for the prevention and treatment of COVID-19. This study will increase the integrity and data transparency of the clinical research process, which is of great significance for improving the practical application of SHHS granules in the future. Methods and analysis: The study was designed as a 7-day, randomized, parallel controlled, open-label, noninferiority clinical trial of positive drugs. A total of 240 patients with mild and moderate COVID-19 will be enrolled and randomly assigned to receive SanHanHuaShi granules or LianHuaQingWen granules treatment in a 1:1 ratio. Disease classification, vital signs, SARS-CoV-2 nucleic acid testing, symptoms, medications, adverse events, and safety evaluations will be recorded at each visit. The primary outcome will be the clinical symptom recovery rate. Secondary outcomes will include the recovery time of clinical symptoms, negative conversion time of SARS-CoV-2 nucleic acid test negative conversion rate, hospitalization time, antipyretic time, rate of conversion to severe patients, and time and rate of single symptom recovery. Adverse incidents and safety assessments will be documented. All data will be analyzed using a predetermined statistical analysis plan, including our method for imputation of missing data, primary and secondary outcome analyses, and safety outcomes. Discussion: The results of this study will provide robust evidence to confirm the effectiveness and safety of SHHS in the treatment of COVID-19. Clinical Trial Registration: http://www.chictr.org.cn. Trial number: ChiCTR2200058080. Registered on 29 March 2022.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liu Y, Chen X, Wang H, et al. Effectiveness and safety analysis of SanHanHuaShi granules for the treatment of coronavirus disease 2019: Study protocol and statistical analysis plan for a randomized, parallel-controlled, open-label clinical trial. Front Pharmacol. 2022. PMID: 36052134. doi:10.3389/fphar.2022.936925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。